Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Normalizing effects of EVP-6124, an α-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia.

Preskorn SH, Gawryl M, Dgetluck N, Palfreyman M, Bauer LO, Hilt DC.

J Psychiatr Pract. 2014 Jan;20(1):12-24. doi: 10.1097/01.pra.0000442935.15833.c5.

PMID:
24419307
2.

Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.

Keefe RS, Meltzer HA, Dgetluck N, Gawryl M, Koenig G, Moebius HJ, Lombardo I, Hilt DC.

Neuropsychopharmacology. 2015 Dec;40(13):3053-60. doi: 10.1038/npp.2015.176. Epub 2015 Jun 19.

3.

The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens.

Huang M, Felix AR, Flood DG, Bhuvaneswaran C, Hilt D, Koenig G, Meltzer HY.

Psychopharmacology (Berl). 2014 Dec;231(23):4541-51. doi: 10.1007/s00213-014-3596-0. Epub 2014 May 9.

PMID:
24810107
4.

Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies.

Barbier AJ, Hilhorst M, Van Vliet A, Snyder P, Palfreyman MG, Gawryl M, Dgetluck N, Massaro M, Tiessen R, Timmerman W, Hilt DC.

Clin Ther. 2015 Feb 1;37(2):311-24. doi: 10.1016/j.clinthera.2014.09.013. Epub 2014 Oct 14.

5.

The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.

Beinat C, Banister SD, Herrera M, Law V, Kassiou M.

CNS Drugs. 2015 Jul;29(7):529-42. doi: 10.1007/s40263-015-0260-0. Review.

PMID:
26242477
6.

EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors.

Prickaerts J, van Goethem NP, Chesworth R, Shapiro G, Boess FG, Methfessel C, Reneerkens OA, Flood DG, Hilt D, Gawryl M, Bertrand S, Bertrand D, König G.

Neuropharmacology. 2012 Feb;62(2):1099-110. doi: 10.1016/j.neuropharm.2011.10.024. Epub 2011 Nov 10.

PMID:
22085888
7.

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.

Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R.

Arch Gen Psychiatry. 2006 Jun;63(6):630-8.

PMID:
16754836
8.

Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.

Houthoofd SA, Morrens M, Sabbe BG.

Clin Ther. 2008 Sep;30(9):1565-89. doi: 10.1016/j.clinthera.2008.09.014. Review.

PMID:
18840365
9.

Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia.

Zhang XY, Liu L, Liu S, Hong X, Chen DC, Xiu MH, Yang FD, Zhang Z, Zhang X, Kosten TA, Kosten TR.

Am J Psychiatry. 2012 Sep;169(9):974-81. doi: 10.1176/appi.ajp.2012.11081289.

PMID:
22952075
10.

Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625.

Marquis KL, Comery TA, Jow F, Navarra RL, Grauer SM, Pulicicchio C, Kelley C, Brennan JA, Roncarati R, Scali C, Haydar S, Ghiron C, Terstappen GC, Dunlop J.

Psychopharmacology (Berl). 2011 Dec;218(4):635-47. doi: 10.1007/s00213-011-2357-6. Epub 2011 Jun 4.

PMID:
21643676
11.

A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.

Akdede BB, Anil Yağcioğlu AE, Alptekin K, Turgut TI, Tümüklü M, Yazici MK, Jayathilake K, Tunca Z, Göğüş A, Meltzer HY.

J Clin Psychiatry. 2006 Dec;67(12):1912-9.

PMID:
17194269
12.

Pharmacological and behavioral profile of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide (EVP-5141), a novel α7 nicotinic acetylcholine receptor agonist/serotonin 5-HT3 receptor antagonist.

Boess FG, de Vry J, Erb C, Flessner T, Hendrix M, Luithle J, Methfessel C, Schnizler K, van der Staay FJ, van Kampen M, Wiese WB, König G.

Psychopharmacology (Berl). 2013 May;227(1):1-17. doi: 10.1007/s00213-012-2933-4. Epub 2012 Dec 16.

PMID:
23241647
13.

Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy.

Deutsch SI, Schwartz BL, Schooler NR, Brown CH, Rosse RB, Rosse SM.

Schizophr Res. 2013 Aug;148(1-3):138-44. doi: 10.1016/j.schres.2013.05.023. Epub 2013 Jun 13.

14.

Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.

Geffen Y, Keefe R, Rabinowitz J, Anand R, Davidson M.

J Clin Psychiatry. 2012 Sep;73(9):e1168-74. doi: 10.4088/JCP.12m07642.

PMID:
23059159
15.

A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia.

Haig GM, Bain EE, Robieson WZ, Baker JD, Othman AA.

Am J Psychiatry. 2016 Aug 1;173(8):827-35. doi: 10.1176/appi.ajp.2015.15010093. Epub 2016 Mar 4.

PMID:
26940805
16.

A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia.

Umbricht D, Keefe RS, Murray S, Lowe DA, Porter R, Garibaldi G, Santarelli L.

Neuropsychopharmacology. 2014 Jun;39(7):1568-77. doi: 10.1038/npp.2014.17. Epub 2014 Jan 27.

17.

Continuous infusion of the α7 nicotinic acetylcholine receptor agonist EVP-6124 produces no signs of tolerance at memory-enhancing doses in rats: a pharmacokinetic and behavioral study.

van Goethem NP, Prickaerts J, Welty D, Flood DG, Koenig G.

Behav Pharmacol. 2015 Jun;26(4):403-6. doi: 10.1097/FBP.0000000000000134.

PMID:
25794332
18.

Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia.

Walling D, Marder SR, Kane J, Fleischhacker WW, Keefe RS, Hosford DA, Dvergsten C, Segreti AC, Beaver JS, Toler SM, Jett JE, Dunbar GC.

Schizophr Bull. 2016 Mar;42(2):335-43. doi: 10.1093/schbul/sbv072. Epub 2015 Jun 12.

19.

A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia.

Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, Fennig S, Treves I, Kron S.

J Clin Psychiatry. 2010 Feb;71(2):138-49. doi: 10.4088/JCP.08m04666yel. Epub 2009 Nov 3.

PMID:
19895780
20.

Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist.

Piskulić D, Olver JS, Maruff P, Norman TR.

Hum Psychopharmacol. 2009 Aug;24(6):437-46. doi: 10.1002/hup.1046.

PMID:
19637398

Supplemental Content

Support Center